Caribou Biosciences, Inc. is a leading clinical-stage CRISPR genome editing biotechnology company that develops transformative gene-based medicines for serious diseases. The company's proprietary CRISPR/Cas9 gene editing technology enables precise, directed changes to genomic DNA. Caribou has a leading intellectual property portfolio, several wholly-owned and partnered therapeutic programs in development, and a preclinical pipeline of genome-edited cell therapies for various oncology indications.